OTC sucralfate/H2 blocker/antacid combos get FDA go-ahead for clinical trials.
This article was originally published in The Tan Sheet
Executive Summary
OTC SUCRALFATE/H2 BLOCKER/ANTACID COMBOS CLINICAL TRIALS CLEARED by FDA, sponsor Ashley Downs Pharmaceutical announced. Investigational New Drug application #51,622 is for liquid sucralfate/magaldrate, called Sucralate or Sucrate; IND #51,623 is for chewable sucralfate/calcium carbonate (Caralox); and IND #51,624 is for chewable sucralfate/calcium carbonate/ranitidine (unnamed). The company plans to seek OTC approval for treatment of heartburn.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning